Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

External Control Arms in Oncology: Current Use and Future Directions

(2022) P.S. Mishra-Kalyani et al.   ANNALS OF ONCOLOGY

NRG/RTOG 1122: A phase 2, double‐blinded, placebo‐controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma

(2020) Eudocia Q. Lee et al.   CANCER

Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis

(2020) Michael T. C. Poon et al.   Scientific Reports

A Randomized Double-Blind Placebo-Controlled Phase 2 Trial Of Dendritic Cell Vaccine ICT-107 In Newly Diagnosed Patients With Glioblastoma

(2019) Patrick Y. Wen et al.   CLINICAL CANCER RESEARCH

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

(2018) Linda M. Liau et al.   Journal of Translational Medicine

The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?

(2018) Alyssa M Vanderbeek et al.   NEURO-ONCOLOGY

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

(2018) Alba A. Brandes et al.   ONCOLOGIST

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

(2018) Giuseppe Lombardi et al.   LANCET ONCOLOGY

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma

(2018) Yoshitaka Narita et al.   NEURO-ONCOLOGY

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine–DNA Methyltransferase Biomarker Analyses

(2017) Timothy Cloughesy et al.   JOURNAL OF CLINICAL ONCOLOGY

Adult Glioblastoma

(2017) Brian M. Alexander et al.   JOURNAL OF CLINICAL ONCOLOGY

Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape

(2017) Benjamin M. Ellingson et al.   JOURNAL OF NEURO-ONCOLOGY

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma

(2016) Alba A. Brandes et al.   NEURO-ONCOLOGY

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment

(2015) Hinke F. van Thuijl et al.   ACTA NEUROPATHOLOGICA

Somatic mutations in glioblastoma are associated with methylguanine-DNA methyltransferase methylation

(2015) KERRIE L. MCDONALD et al.   Oncology Letters

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Standards of care for treatment of recurrent glioblastoma—are we there yet?

(2012) Michael Weller et al.   NEURO-ONCOLOGY

Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research

(2012) James E. Signorovitch et al.   VALUE IN HEALTH

Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy

(2010) Robert M. Prins et al.   CLINICAL CANCER RESEARCH

Immune responses to malignancies

(2010) Theresa L. Whiteside   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY